{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:14:55Z","timestamp":1770761695738,"version":"3.50.0"},"reference-count":71,"publisher":"Informa UK Limited","issue":"17","funder":[{"name":"Shionogi Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2015,11,22]]},"DOI":"10.1517\/14656566.2015.1109627","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T21:47:38Z","timestamp":1449179258000},"page":"2703-2714","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use"],"prefix":"10.1517","volume":"16","author":[{"given":"JoAnn V","family":"Pinkerton","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Kagan","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Papers of special note have been highlighted as of considerable interest (\u2022\u2022) to readers."},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1216280"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e3182a122c2"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01335.x"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S44579"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12190"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.4137\/CMRH.S14498"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12235"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000329"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000196"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8063"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0413"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000316"},{"key":"e_1_3_1_16_1","volume-title":"Osphena\u2122 (ospemifene). [prescribing information]","year":"2013","unstructured":"Osphena\u2122 (ospemifene). [prescribing information]. Florham Park (NJ): Shionogi, Inc; 2013."},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3243"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3254"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000365"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2013.04.004"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.2.7342"},{"issue":"1","key":"e_1_3_1_22_1","first-page":"27","article-title":"Effects of the selective estrogen receptor modulator ospemifene on bone in rats","volume":"46","author":"Kangas L","year":"2014","unstructured":"Kangas L, Harkonen P, Vaananen K, et al. Effects of the selective estrogen receptor modulator ospemifene on bone in rats. Horm Metab Res. 2014;46(1):27\u201335.","journal-title":"Horm Metab Res"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1367032"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(01)00066-8"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S39146"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181c1ac01"},{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e318279ba64"},{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2014.02.015"},{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.12.005"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31826d36ba"},{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2013.834493"},{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590410001672197"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-006-0689-9"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.071206"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000419"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181a7fb1e"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.06.008"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181b7c65f"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2013.09.003"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e318223e82a"},{"key":"e_1_3_7_11_1","volume-title":"Evista\u00ae. [prescribing information]","year":"2014","unstructured":"Evista\u00ae. [prescribing information]. Indianapolis (IN): Eli Lilly and Company; 2014."},{"issue":"6","key":"e_1_3_7_12_1","first-page":"2197","article-title":"A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women","volume":"85","author":"Prestwood KM","year":"2000","unstructured":"Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85(6):2197\u20132202.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050236"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60140-3"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(99)00554-2"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2008.01.017"},{"key":"e_1_3_7_17_1","volume-title":"Novaldex\u00ae. [prescribing information]","year":"2006","unstructured":"Novaldex\u00ae. [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2006."},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261302"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(98)00117-1"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e31829755ed"},{"key":"e_1_3_7_21_1","volume-title":"Duavee\u00ae. [prescribing information]","year":"2013","unstructured":"Duavee\u00ae. [prescribing information]. Philadelphia (PA): Wyeth Pharmaceuticals Inc; 2013."},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2014.07.012"},{"key":"e_1_3_7_23_1","volume-title":"Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation","author":"FDA Guidance for Industry","year":"2003","unstructured":"FDA Guidance for Industry. Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation. Rockford (MD): US Food and Drug Administration; 2003."},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2014.954996"},{"key":"e_1_3_7_25_1","unstructured":"Kagan R Portman D Archer DF et al. Responder analysis of ospemifene treatment for vulvar and vaginal atrophy in postmenopausal women in phase 3 randomized placebo-controlled in trials. Paper presented at: North American Menopause Society 25th Annual Meeting; 2014 Oct 15\u201318; Washington DC."},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12428"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2011.2839"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000275"},{"key":"e_1_3_8_2_1","unstructured":"Pinkerton JV Archer DF Graham S et al. Effect of ospemifene on vasomotor symptoms in postmenopausal women. North American Menopause Society 25th Annual Meeting; 2014 Oct 14\u201318; Washington DC."},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e318291ef83"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01390-4"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.374"},{"key":"e_1_3_8_6_1","first-page":"CD007063","article-title":"Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women","volume":"9","author":"Ismail SI","year":"2010","unstructured":"Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev. 2010;9:CD007063.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-07-0468"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13697130903010953"},{"key":"e_1_3_8_9_1","volume-title":"Senshio product information","year":"2015","unstructured":"Senshio product information. South Wales: Penn Pharmaceutical Services Ltd; 2015."},{"key":"e_1_3_8_10_1","volume-title":"Senshio summary of opinion","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2014","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Senshio summary of opinion. London: European Medicines Agency; 2014."},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e31826560da"},{"issue":"1","key":"e_1_3_8_12_1","first-page":"45","article-title":"Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women","volume":"10","author":"Pinkerton JV","year":"2003","unstructured":"Pinkerton JV, Shifren JL, La VJ, et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause. 2003;10(1):45\u201352.","journal-title":"Menopause"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.08.050"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1014799"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2012.12.002"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2015.1109627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:30:14Z","timestamp":1770391814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2015.1109627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,22]]},"references-count":71,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,11,22]]}},"alternative-id":["10.1517\/14656566.2015.1109627"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2015.1109627","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}